SMT D002

Drug Profile

SMT D002

Alternative Names: DL 06003; SMT-D002

Latest Information Update: 14 Mar 2013

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Summit plc
  • Class Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Seborrhoeic dermatitis

Most Recent Events

  • 14 Mar 2013 No development reported - Phase-I for Seborrhoeic dermatitis in USA (PO)
  • 15 Apr 2008 Final efficacy data from a second phase I trial in Seborrhoea released by Summit
  • 23 Oct 2007 Summit plc has completed enrolment and initiated dosing in a second phase I trial for seborrhoea in the UK
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top